[A15-50] Nivolumab - Addendum to Commission A15-27
Last updated 07.01.2016
Project no.:
A15-50
Commission:
Commission awarded on 25.11.2015 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair, Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-40 | Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A15-27 | Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-01-07 A G-BA decision was published.